What's in XenoPort, Inc.'s pipeline?

XenoPort, Inc. has 12 drugs in our index: 3 marketed, 0 filed, 4 in Phase 3, 2 in Phase 2, 3 in Phase 1.

Which companies overlap with XenoPort, Inc.'s portfolio?

Top competitors by shared drug class: Pfizer, Bial - Portela C S.A., Eisai Inc., Formation Bio, Inc., IRCCS San Raffaele Roma.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/xenoport-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

XenoPort, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

XenoPort, Inc. pipeline: 3 marketed, 0 filed, 4 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 4 Phase 3 2 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
GSK1838262 Placebo match	GSK1838262 Placebo match	marketed
GSK1838262 600 mg	GSK1838262 600 mg	marketed
Sinemet (comparator)	Sinemet (comparator)	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic L-amino acid decarboxylase (AADC); dopaminergic system	Neurology
GEn (XP13512)	GEn (XP13512)	phase 3	Gabapentin prodrug / Anticonvulsant	LAT1 (Large Neutral Amino Acid Transporter 1)	Neurology
XP13512 (GSK1838262)	XP13512 (GSK1838262)	phase 3	sodium channel blocker	Voltage-gated sodium channels	Neurology
XP13512 (GEn)	XP13512 (GEn)	phase 3
GSK1838262 Extended Release Tablets	GSK1838262 Extended Release Tablets	phase 3	SGLT1 inhibitor	SGLT1 (sodium-glucose cotransporter 1)	Diabetes

Therapeutic area mix

Neurology · 3
Diabetes · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Pfizer · 2 shared drug classes
Bial - Portela C S.A. · 1 shared drug class
Eisai Inc. · 1 shared drug class
Formation Bio, Inc. · 1 shared drug class
IRCCS San Raffaele Roma · 1 shared drug class
Intec Pharma Ltd. · 1 shared drug class
NeuroDerm Ltd. · 1 shared drug class
Ross D. Zafonte, MD · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for XenoPort, Inc.:

Cite this brief

Drug Landscape (2026). XenoPort, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/xenoport-inc. Accessed 2026-06-10.